343-10-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoro-4-hydroxyquinoline-3-carboxylic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Biochemical Research:
6-Fluoro-4-hydroxyquinoline-3-carboxylic acid is used as a research tool in biochemical studies, where its properties can be explored to understand its interactions with biological molecules and its potential applications in drug discovery. This may include investigating its binding affinity to enzymes, receptors, or other target proteins, as well as its potential role in modulating cellular processes.
Used in Organic Chemistry:
6-Fluoro-4-hydroxyquinoline-3-carboxylic acid is used as a reagent or catalyst in various organic synthesis processes. Its functional groups can participate in a range of chemical reactions, such as esterification, amidation, or condensation, making it a versatile component in the synthesis of complex organic molecules.
Used in Material Science:
6-Fluoro-4-hydroxyquinoline-3-carboxylic acid may be used in the development of new materials with specific properties, such as optical, electronic, or catalytic characteristics. Its unique structure and functional groups could contribute to the creation of novel materials with potential applications in various industries, including electronics, energy, or environmental protection.

Upstream product

• 251986-57-9 4,5-dimethoxycarbonyl-1-(4'-fluorophenyl)-1H-pyrrole-2,3-dione 
• 251986-69-3 6-fluoro-4-oxo-1,4-dihydro-quinoline-2,3-dicarboxylic acid 3-methyl ester 
• 251986-63-7 dimethyl 6-fluoro-4-oxo-1,4-dihydroquinoline-2,3-dicarboxylate 
• 251986-49-9 methyl 3-carbomethoxy-3-(4'-fluorophenyl)amino-2-propenoate 
• 371-40-4 4-fluoroaniline 
• 26832-96-2 diethyl 2-(4-fluoroanilino)methylenemalonate 
• 71083-00-6 ethyl 6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 144216-13-7 6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methyl ester 
• 318-35-4 ethyl 6-fluoro-4-hydroxy-3-quinoline-carboxylate 

Downstream Products

• 391-78-6 6-Fluoro-4-hydroxyquinoline 
• 103802-26-2 N,4-dihydroxy-6-fluoro-N-phenyl-3-quinoline carboxamide 
• 873051-19-5 N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 391-77-5 4-Chloro-6-fluoroquinoline 

Relevant academic research and scientific papers

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents

Thirty-one 4-oxoquinoline-3-carboxamides derivatives were synthesized and evaluated for their anti-fibrotic activities by the inhibition of TGF-β1-induced total collagen accumulation and anti-inflammatory activities by the inhibition of LPS-stimulated TNF-α production. Among them, three compounds (10a, 10l and 11g) exhibited potent inhibitory effects on both TGF-β1-induced total collagen accumulation and LPS-stimulated TNF-α production. Furthermore, oral administrations of 10l at a dose of 20 mg/kg/day for 4 weeks effectively alleviated lung inflammation and injury, and decreased lung collagen accumulation in bleomycin-induced pulmonary fibrosis model. Histopathological evaluation of lung tissue confirmed 10l as a potential, orally active agent for the treatment of pulmonary fibrosis.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors

Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. All the compounds showed high antiviral activities in inhibiting the formation of SIV-induced syncytium in CEM174 cells. Nine of them with low cytotoxicities were evaluated by Tat dependent HIV-1 LTR-driven CAT gene expression colorimetric enzyme assay in human 293T cells, indicating effective inhibitory activities of blocking the Tat-TAR interaction. Molecular modeling experiments indicated that these compounds may inhibit Tat-TAR interaction by binding to Tat protein instead of TAR RNA.

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.

Novel process for preparing 3-fluoroquinolines

The invention relates to a novel preparation of 3-fluoroquinolines of formula (I) in which R1, R2, R3 and R4 represent: a) a fluorine; b) an alkyl optionally substituted with one to three fluorines, with OR

A synthesis of 4-quinolone-3-carboxylic acids via pyrolysis of N- aryldioxopyrrolines

A synthesis of 4-quinolone-3-carboxylic acids (8) was achieved by pyrolysis of 4,5-dimethoxycarbonyl-1-aryl-1H-pyrrole-2,3-diones (3) followed by selective demethoxycarbonylation of the resulting 2,3-dimethoxycarbonyl-4- quinolones (4) in excellent overall yields.

Synthesis of fluoro-4-hydroxyquinoline-3-carboxylic acids by the Gould-Jacobs reaction

The synthesis of several fluoro-4-hydroxyquinoline-3-carboxylic acids by the Gould-Jacobs reaction is presented. These quinolines are important intermediates for the preparation of antibacterial fluoroquinolones.